Assessment of TLR immunomodulators in oncology and HIV

Challenge:  A European publicly-listed biotech was facing a Phase III milestone for its lead immunomodulator and had a next generation technology in IND-enabling studies. The company was operating in...
Learn More

Deal benchmarks & term sheet appraisal for an early-stage license deal

Project Challenge: An early stage investor was in the midst of setting up a NewCo for the research and development of novel treatments using a fairly under-researched area of cell biology. However, a...
Learn More

Investor due diligence of a development-stage microbiome company

Due Diligence Challenge: An investor was considering re-investing into a development-stage microbiome company that had experienced certain issues that delayed timelines and changed the risk profile....
Learn More

Investor Due Diligence: Pharma Business Development Case Studies

Alacrita frequently works on behalf of investors to conduct due diligence on prospective transactions. The two case studies below offer a snapshot of the typical expertise we provide in this area. To...
Learn More

Virtual Stewardship of a Targeted Cancer Therapy to an IND Submission

An early-stage biotech company developing a targeted cancer therapy engaged Alacrita to provide expertise to help them navigate an upcoming IND submission. An Alacrita partner and medical oncologist...
Learn More

Pharmaceutical Licensing: Negotiation Support

Alacrita provides support to organizations seeking pharmaceutical licensing opportunities, both in- and out-licensing, as well as negotiation support. Our approach is flexible and can be tailored...
Learn More

Due diligence: biologic technologies & phase III probability of success of CNS asset

Case Study 1, Challenge: A mid-size pharmaceutical company seeking opportunities to diversify within its core therapeutic area by partnering in products based on biologic technologies retained...
Learn More

Due diligence: plasma protein manufacturer; Phase III gene therapy asset

Case Study 1, Challenge: A private equity investor was considering a transaction in a company supplying therapeutic proteins derived from biological sources for the treatment of numerous diseases in...
Learn More

Developing an independent market report for a cannabinoid company seeking a dual-listing

Challenge: A company developing a portfolio of therapeutic cannabinoids for neurological conditions was seeking a stock exchange listing and asked Alacrita to develop documentation supporting its...
Learn More

Roadmap for commercial data infrastructure build to support rare disease drug launch

Challenge: Our client was a clinical-stage biotech in the process of early stage planning for the launch of its first drug, a small molecule treatment for a rare endocrine disorder. However, the...
Learn More

University life sciences IP and project portfolio review

Challenge: Alacrita developed techno-commercial development plans for selected top priority projects. The client, King's Commercialisation Institute, convened an expert panel which then selected...
Learn More

Commercial development plan for a mesenchymal stem cell therapy in acute GvHD

Challenge: Our client was a leading UK Research Institute requiring assistance in assigning internal commercialization funding to the most promising research groups within the university. Alacrita...
Learn More
1 2 3 4 5 ... 19
Next

Facing a complex life science challenge? We can help.

Contact us today to learn how our pharma & biotech consulting expertise can serve your project.

Contact us

Explore our life science consulting services

© 2021 Alacrita Holdings Limited   |  Life Science, Biotech & Pharmaceutical Consulting

Alacrita Life Science Consulting 
2 Royal College St
London, UK
NW1 0NH

Registered in England & Wales.
No. 10530608


One Broadway
Floor 14
Cambridge, MA 02142

Registered in Massachusetts.